FDA approves frontline Keytruda in unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.
A phase 2 trial led by a NewYork-Presbyterian/Weill Cornell Medicine oncologist reveals the efficacy of neoadjuvant botensilimab plus balstilimab in patients with colorectal cancer.
Blood tests that detect traces of cancer cells and tumor DNA help find residual disease after treatment is completed.
Listen to this episode from The Late Night Oncology Show on Spotify. [Episódio em Inglês] Para fechar o mês de conscientização dos tumores colorretais, recebemos…
A phase 2 trial led by a NewYork-Presbyterian/Weill Cornell Medicine oncologist reveals the efficacy of neoadjuvant botensilimab plus balstilimab in patients with colorectal cancer.
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Objective We evaluated whether people who had not completed a faecal immunochemical test (FIT) for colorectal cancer (CRC) screening would complete a blood-based testing option…
Giving two immunotherapy drugs before surgery to remove colorectal cancer shows highly promising results
Reimagine Cancer Detection, Diagnosis & Patient Management through Harnessing the Potential of Liquid Biopsies
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
